price close busi januari
intuit surgic manufactur da vinci robot
system use wide rang minimally-
biomed devic servic
invest augment robot surgeri growth
isrg competit moat benefit lt
bottom line would buyer weak
presum larg function firm oper expens guidanc
y/i near-term earn model reflect higher spend
guidanc view favor isrg commit invest next-gener technolog
open new market india china taiwan set firm
sustain strong long-term revenu growth maintain domin edg
highlight three pillar underli bullish thesi
invest could augment technolog breadth commerci reach help
firm maintain domin larg grow robot surgeri market
isrg commit invest heavili today portend posit firm long term
view firm invest commerci infrastructur across myriad new
market india taiwan devot increas resourc expand current
nascent market china japan time intuit commit increas
level invest new product innov new technolog believ
invest set firm sustain strong double-digit procedur
growth global maintain competit moat technolog standpoint
drive robot surgeri adopt unpenetr lap/open surgic
awesom financi strength could help expand competit moat
instal base via flexibl financ oper leas percentag total
system placement continu trend higher isrg abil provid
custom financi flexibl support increas access join davinci
ecosystem firm instal base grow believ strengthen
domin isrg ecosystem entrench firm ahead potenti
competit think isrg oper leas strategi repres import
fundament competit advantag expect firm lean go forward
still see huge tam/low penetr think robot surgeri revolut
still earli inning note penetr applic procedur today
still quit low estim procedur rel procedur
moreov given aforement invest firm make
new technolog new market see potenti procedur
expand time
sum view firm aggress invest today harbing sustain
strong growth industry-lead oper margin long term reiter
buy rate year-end price target
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
outlin plan grow total oper expens level
firm doubl short- long-term invest addit
continu support on-going platform launch ion sp advanc
instrument firm commit addit resourc drive long-term
ou market expans name india taiwan china scale
busi well support technolog enhanc informat ar
advanc imag think isrg target invest area magnitud
invest set firm drive strong procedur growth longer term
new market well maintain enhanc competit advantag
flexibl capit financ model serv augment isrg strong
ago financ option continu gain traction total placement
structur oper leas compar
year-ago quarter increasingli flexibl financ option includ
recent introduct usage-bas model isrg current high-
volum center intuit remain focus drive davinci market
expans ahead impend competit firm abl leverag
balanc sheet drive adopt davinci ecosystem intuit behind
establish breadth busi model well align trend
consolid continu play across us healthcar system provid
firm anoth competit advantag platform eventu enter
market continu entrench major healthcar player
hospit center increasingli standard intuit ecosystem
japan stellar recent growth continu region prime serv tailwind
procedur growth japan exceed second straight quarter
continu see increas traction across newli reimburs
effect april procedur firm place system japan
recent quarter bullish sign continu strong growth region go
forward think initi adopt trend japan portend posit long-term
procedur volum growth region especi given reimburs line
laparoscop level suggest desir perform procedur via robot
approach region strong think there lot like around japan
opportun especi given region prefer minim invas
procedur japan prime provid meaning ramp impact
isrg busi throughout beyond
china put take around new quota implic near term view
signific long-term upsid potenti procedur growth china
moder expect region transit tailwind begin
increas impact beyond end octob
nhfpc china announc new quota call system
mainland china prior end prior quota china cover
system coupl system militari centers/hong kong current
system region repres busiest davinci system world
strong pent-up demand addit capit wed note quota cover
surgic robot platform specif isrg platform competitor
gain market approv region prior year-end portion
quota could go non-davinci platform separ tariff robot
impos given high system util strong demand today dont
view tariff materi deterr adopt anticip minim
system placement hospit go
tender process take time china increasingli becom
biomed devic servic
tailwind throughout addit given xi current
approv china expect center hold xi clear
china current repres isrg total revenu see substanti
upsid go forward system instal schedul nearli tripl
sp initi limit roll-out on-going announc fda clearanc
urolog surgic procedur da vinci sp singl port system earli
june firm commenc measur launch platform
three system ship us market place addit
system sp near-term impact top line minim
firm focus build clinic data ad addit indic tor
submit recent think sp abil augment isrg current
robot surgeri product portfolio via platform abil access site
natur orific thu expand reach firm domin robot
ecosystem medium term establish entrench
top player robot field sp urolog indic first step
think futur sp indic submiss tor colorect import
busi abil augment overal procedur growth
remain suppli constrain today build product repres
key short-term invest firm firm continu work
suppli chain optim target broader market launch firm
secur addit indic
guidanc reiter manag yesterday reiter guidanc
expect total procedur volum growth rang approxim
margin rang manag expect pro forma opex
growth rang level firm current project
incom tax rang
figur intuit surgic result vs cg estim consensu project
biomed devic servic
deriv price target appli premium mean large-cap
med-tech price-to-earnings multipl appli ep model
forward ep compound-annual-growth-rate thu aforement target multipl drive
target price-to-earnings appli pro forma ep estim
deriv target
biomed devic servic
p/e/g valuat financi metric use mean ex-outli large-cap med-tech price-to-earnings p/e/g multipl ep pro forma premium b/c price-to-earnings multipl use group forma price figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
biomed devic servic
million except per share total servic total gross total oper oper incom expens pre-tax incom tax expens tax incom net loss attribut nonconttol interest jv- net incom attribut share ep pro-forma calcul xi trade-in programshar base compens intang liabil litig invest net forma ex tax analysisduct adjust sbc ia margin pro margin includ margin pro incom cont figur revenu model
biomed devic servic
revenu tabl motion upgrade/oper leas total total instrument/access total servic total revenu growth modelgrowth rate assumptionsu system unit sale replacements/trad instal base us total total sold ex-oper asp leas total asp per oper modelgrowth rate procedur growth procedur growth procedur growth gener ou urolog gener gynecolog us ww procedur asp revenue/instal system intuit surgic
